TRIP10 and triple-negative breast carcinoma: For example, TRIP10 downstream effector of CDC42 is hyperphosphorylated in non-responder cohorts and in triple negative breast cancer, the hypermethylation of TRIP10 is related with the prediction of response to neoadjuvant chemotherapy (Pineda et al., 2019).